Plain-English translation of NCT05188313 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This trial is testing whether adding two medications called and to standard chemotherapy and radiation treatment can help people with esophageal adenocarcinoma (a specific type of esophageal cancer) live longer. Both medications are antibodies that target a protein called HER2 that appears on certain cancer cells. The study will compare people who receive the standard treatment alone with those who receive the standard treatment plus the medication.
Current treatments for this type of esophageal cancer have limited success—most people survive less than four years even with the best available care. This treatment aims to personalize care by targeting the HER2 protein specifically, potentially improving survival rates for patients whose cancer has this protein.
You likely qualify if…
You likely don't qualify if…
If you enroll, you will be randomly assigned to receive either the standard chemotherapy and radiation treatment alone, or the same treatment combined with the two targeted antibody medications given intravenously on specific days. The chemotherapy and radiation will happen over about 5–6 weeks, with the antibody medications given on days 1, 22, 43, 64, and 85. After treatment, you will have surgery to remove the cancer, followed by regular follow-up visits to monitor your health and how long you survive.
AI-generated summary from trial data · Jul 4, 2026 · Not medical advice
Netherlands